These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 6952947)

  • 41. Current status of blastic transformation in chronic myelogenous leukemia.
    Barton JC; Conrad ME
    Am J Hematol; 1978; 4(3):281-91. PubMed ID: 362906
    [No Abstract]   [Full Text] [Related]  

  • 42. Sequential transformation of t(8;13)-related disease: a case report.
    Roy S; Szer J; Campbell LJ; Juneja S
    Acta Haematol; 2002; 107(2):95-7. PubMed ID: 11919389
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Histamine contents of blood plasma and cells in patients with myelogenous leukemia.
    Suzuki S; Ishida F; Kono T; Muranaka M
    Cancer; 1971 Aug; 28(2):384-8. PubMed ID: 5284464
    [No Abstract]   [Full Text] [Related]  

  • 44. [Chronic myelogenous leukemia. Acute transformation].
    Uzuka Y
    Rinsho Ketsueki; 1984 Mar; 25(3):288-98. PubMed ID: 6590887
    [No Abstract]   [Full Text] [Related]  

  • 45. [Heterogeneity of leukemia cell phenotype. I. Variants of hetero- phenotype in relation to myeloid and erythrocytic markers of leukemic cells in acute leukemia and blast crisis of chronic myeloproliferative disorders].
    Kemnitz J; Helmke M; Frend M; Bür T; Dominis M; Horitz H
    Gematol Transfuziol; 1990 Aug; 35(8):9-14. PubMed ID: 2253865
    [No Abstract]   [Full Text] [Related]  

  • 46. Serum erythropoietin (ESF) levels and erythroid progenitors (CFU-Es) of patients with chronic myeloproliferative disorders.
    Fukushima Y; Miura I; Takahashi T; Fukuda M; Yoshida K; Yamaguchi A; Miura AB
    Tohoku J Exp Med; 1984 Apr; 142(4):399-407. PubMed ID: 6588639
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clonal heterogeneity as a driver of disease variability in the evolution of myeloproliferative neoplasms.
    Prick J; de Haan G; Green AR; Kent DG
    Exp Hematol; 2014 Oct; 42(10):841-51. PubMed ID: 25201757
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Pathology of myeloproliferative disorders and related diseases].
    Motoi M
    Rinsho Ketsueki; 1988 Jul; 29(7):969-76. PubMed ID: 3184483
    [No Abstract]   [Full Text] [Related]  

  • 49. An unusual form of chronic myeloproliferative disorder. Aleukemic basophilic leukemia.
    Lertprasertsuke N; Tsutsumi Y
    Acta Pathol Jpn; 1991 Jan; 41(1):73-81. PubMed ID: 2031458
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hematopoietic stem cells: cancer involvement and myeloid leukemia.
    Li XL; Xue Y; Yang YJ; Zhang CX; Wang Y; Duan YY; Meng YN; Fu J
    Eur Rev Med Pharmacol Sci; 2015 May; 19(10):1829-36. PubMed ID: 26044227
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Radioimmunometric determination of histamine in myeloproliferative syndromes].
    Bettelheim P; Valent P
    Wien Klin Wochenschr; 1989 Oct; 101(20):706-10. PubMed ID: 2480027
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In vitro culture techniques defining biological abnormalities in the myelodysplastic syndromes and myeloproliferative disorders.
    Greenberg PL
    Clin Haematol; 1986 Nov; 15(4):973-93. PubMed ID: 3552351
    [No Abstract]   [Full Text] [Related]  

  • 53. Growth characteristics of leukemic and normal hematopoietic cells in Ph' + chronic myelogenous leukemia and effects of intensive treatment.
    Goto T; Nishikori M; Arlin Z; Gee T; Kempin S; Burchenal J; Strife A; Wisniewski D; Lambek C; Little C; Jhanwar S; Chaganti R; Clarkson B
    Blood; 1982 Apr; 59(4):793-808. PubMed ID: 6949617
    [No Abstract]   [Full Text] [Related]  

  • 54. Is the maturation arrest in myeloid leukemia reversible?
    Olsson I
    Acta Med Scand; 1983; 214(4):261-72. PubMed ID: 6318523
    [No Abstract]   [Full Text] [Related]  

  • 55. The clinical significance of serum transcobalamins in myeloid leukemia and other myeloproliferative disorders.
    Rachmilewitz B; Rachmilewitz M
    Isr J Med Sci; 1977 Jul; 13(7):710-5. PubMed ID: 270474
    [No Abstract]   [Full Text] [Related]  

  • 56. Malignancies of natural killer (NK) cell precursor: myeloid/NK cell precursor acute leukemia and blastic NK cell lymphoma/leukemia.
    Suzuki R; Nakamura S
    Leuk Res; 1999 Jul; 23(7):615-24. PubMed ID: 10400182
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Origin of chronic myelocytic leukemia in a precursor of pre-B lymphocytes.
    LeBien TW; Hozier J; Minowada J; Kersey JH
    N Engl J Med; 1979 Jul; 301(3):144-7. PubMed ID: 313004
    [No Abstract]   [Full Text] [Related]  

  • 58. [Neoplastic transformation of the pluripotential stem cell. I. Possible molecular mechanisms of neoplastic transformation].
    Rupniewska ZM
    Acta Haematol Pol; 1985; 16(1-2):90-101. PubMed ID: 3914172
    [No Abstract]   [Full Text] [Related]  

  • 59. Plasma fucosyltransferase as an indicator of imminent blastic crisis.
    Shah-Reddy I; Kessel DH; Chou TH; Mirchandani I; Khilanani U
    Am J Hematol; 1982 Feb; 12(1):29-37. PubMed ID: 6950663
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Glycosaminoglycans in leukocytes in myeloproliferative disorders].
    Kharchenko MF; Shatskaia TL; Ostroumova SS; Rybakova LP; Shcherbakova EG
    Vopr Med Khim; 1984; 30(4):86-91. PubMed ID: 6594825
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.